Besponsa
.25 mg/mL · Injection, Powder, Lyophilized, for Solution
- Prescription only
- CD22-directed Immunoconjugate
- Active substance
- Inotuzumab Ozogamicin
- Made by
- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Details
| Made by | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
|---|---|
| Active substance | Inotuzumab Ozogamicin |
| Strength | .25 mg/mL |
| Form | Injection, Powder, Lyophilized, for Solution |
| Route | Intravenous |
| Packs | 1 VIAL, SINGLE-DOSE in 1 CARTON / 4 mL in 1 VIAL, SINGLE-DOSE |
| NDC | 0008-0100 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).